Periodontitis – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Periodontitis – Drugs In Development, 2024 report and make more profitable business decisions.
Periodontitis is a gum infection that damages the soft tissue and destroys the bone that supports teeth. Signs and symptoms of periodontitis include swollen gums, bright red or purplish gums, bad breath, and spaces developing between teeth. Risk factors include gingivitis, heredity, diabetes, age, substance abuse, and a weakened immune system.
The Periodontitis drugs in development market research report provide comprehensive information on the therapeutics under development for Periodontitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Periodontitis and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Periodontitis | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 20 molecules, with 16 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Periodontitis therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Periodontitis pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Periodontitis treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
Amyndas Pharmaceuticals LLCBeijing SH biotechnology Co Ltd
Cellatoz Therapeutics Inc
Cells for Cells SA
Cytopeutics Pte Ltd
Denteric Pty Ltd
Geistlich Pharma AG
GEXVal Inc
KIMS Pharmaceutical Co Ltd
MetiMedi Pharmaceuticals Co Ltd
Noveome Biotherapeutics Inc
PerioTrap Pharmaceuticals GmbH
True Node Sciences Inc
University of Louisville
University of Malaya
University of Pennsylvania
Virtici LLC
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Periodontitis reports